Influenza, a recurring seasonal disease, causes over 5 million of illnesses annually worldwide and threatens the health of susceptible groups, including elderly people and children. Although several effective drugs such as neuraminidase inhibitors against influenza viruses have been marketed, the rapid evolution of new variants every flu season and the occurrence of resistant subtypes present a challenge to the prevention and treatment of influenza. This review chooses two representative anti-influenza drugs, oseltamivir (Tamiflu) and baloxavir (Xofluza), elucidating their origin, mode of action, chemical synthesis, and a brief comparison between them is made. Both of the drugs highlight the importance of structure-based design in pharmacy, providing insights in development of a new drug. Other strategies against influenza, including vaccination, are also discussed.
|